13F-HR filed by GREAT POINT PARTNERS LLC
GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2016-06-30, filed 2016-08-15, with 39 holding rows worth $349,225,000.
- Accession
- 0000930413-16-007885
- Filer
- CIK 1281446
- Filed
- 2016-08-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2016
A holdings report, 39 entries on the cover page, a total value of $349,225,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $349,225,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerJAY JEFFREY R028-12517
- included managerKROIN DAVID028-13262
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ADAMAS PHARMACEUTICALS INC | 00548A106 | COM | 2,109,099 | $31,932,000 | thousands by filing date | |
| VANDA PHARMACEUTICALS INC | 921659108 | COM | 2,705,758 | $30,277,000 | thousands by filing date | |
| SYNERGY PHARMACEUTICALS DEL | 871639308 | COM NEW | 7,590,000 | $28,842,000 | thousands by filing date | |
| EXELIXIS INC COM | 30161Q104 | Stock | 3,200,000 | $24,992,000 | thousands by filing date | |
| DERMIRA INC | 24983L104 | COM | 800,000 | $23,400,000 | thousands by filing date | |
| BLUEBIRD BIO INC | 09609G100 | COM | 500,000 | $21,645,000 | thousands by filing date | |
| NEUROCRINE BIOSCIENCES INC | 64125C109 | COM | 470,000 | $21,362,000 | thousands by filing date | |
| EAGLE PHARMACEUTICALS INC | 269796108 | COM | 548,290 | $21,268,000 | thousands by filing date | |
| ZOGENIX INC. | 98978L204 | Common Stock | 2,440,959 | $19,650,000 | thousands by filing date | |
| IGNYTA INC | 451731103 | COM | 3,238,703 | $17,554,000 | thousands by filing date | |
| ENANTA PHARMACEUTICALS INC | 29251M106 | COM | 538,024 | $11,863,000 | thousands by filing date | |
| SAGE THERAPEUTICS INC | 78667J108 | COM | 330,000 | $9,943,000 | thousands by filing date | |
| TETRAPHASE PHARMACEUTICALS INC | 88165N105 | COMMON STOCK | 2,299,529 | $9,888,000 | thousands by filing date | |
| CONNECTURE INC COM | 20786J106 | Stock | 4,127,232 | $9,328,000 | thousands by filing date | |
| XENCOR INC | 98401F105 | COMMON STOCK | 450,000 | $8,546,000 | thousands by filing date | |
| AURINIA PHARMACEUTICALS INC COM | 05156V102 | Stock | 2,457,144 | $7,192,000 | thousands by filing date | |
| Alcobra Ltd | M2239P109 | SHS | 1,414,573 | $6,351,000 | thousands by filing date | |
| RAPTOR PHARMACEUTICAL CORP | 75382F106 | COM | 978,350 | $5,254,000 | thousands by filing date | |
| SAREPTA THERAPEUTICS INC | 803607100 | COM | 238,900 | $4,556,000 | thousands by filing date | call |
| SUNESIS PHARMACEUTICALS INC | 867328601 | COM NEW | 8,173,937 | $4,477,000 | thousands by filing date | |
| BOVIE MEDICAL CORP | 10211F100 | COM | 2,680,000 | $4,395,000 | thousands by filing date | |
| ARADIGM CORP | 038505400 | COM NO PAR NEW | 1,002,962 | $4,383,000 | thousands by filing date | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 100,000 | $3,882,000 | thousands by filing date | |
| OCERA THERAPEUTICS INC COM | 67552A108 | COM | 1,963,777 | $3,731,000 | thousands by filing date | |
| SERES THERAPEUTICS INC | 81750R102 | COM | 120,000 | $3,486,000 | thousands by filing date | put |
| TENAX THERAPEUTICS INC | 88032L100 | COM | 1,108,593 | $2,838,000 | thousands by filing date | |
| FOAMIX PHARMACEUTICALS LTD | M46135105 | SHS | 274,756 | $1,745,000 | thousands by filing date | |
| Adverum Biotechnologies, Inc. | 00773U108 | Common Stock | 550,116 | $1,738,000 | thousands by filing date | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 76,511 | $1,015,000 | thousands by filing date | |
| CALADRIUS BIOSCIENCES INC | 128058104 | Cmn | 1,525,244 | $900,000 | thousands by filing date | |
| DIPEXIUM PHARMACEUTICALS INC | 25456J104 | COM | 87,914 | $871,000 | thousands by filing date | |
| VERICEL CORP | 92346J108 | COM | 253,502 | $570,000 | thousands by filing date | |
| PARATEK PHARMACEUTICALS INC | 699374302 | Equity | 29,266 | $407,000 | thousands by filing date | |
| AXOVANT SCIENCES LTD | G0750W104 | COM | 25,000 | $321,000 | thousands by filing date | |
| REVANCE THERAPEUTICS INC | 761330109 | COM | 21,665 | $295,000 | thousands by filing date | |
| STREAMLINE HEALTH SOLUTIONS | 86323X106 | COM | 151,611 | $182,000 | thousands by filing date | |
| RIGEL PHARMACEUTICALS INC | 766559603 | COMMON STOCK | 50,000 | $112,000 | thousands by filing date | |
| ARDELYX INC | 039697107 | COM | 3,444 | $30,000 | thousands by filing date | |
| AMARIN CORP PLC | 023111206 | SPONS ADR NEW | 2,000 | $4,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000930413-16-007885 | this filing | 2016-08-15 | acceptance time not in the bulk data set |